The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients

Clinical and Experimental Nephrology

Volumn 17, Issue 3, 2013, Pages 416-423

  Deger, Serpil Muge ^a,b   Erten, Yasemin ^a   Pasaoglu, Ozge Tugce ^a   Derici, Ulver Boztepe ^a   Reis, Kadriye Altok ^a   Onec, Kursad ^a   Pasaoglu, Hatice ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dialysis; FGF23; Iron therapy; Mineral metabolism

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; IRON; PHOSPHATE;

ADULT; AGE DISTRIBUTION; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG TARGETING; FEMALE; FERRITIN BLOOD LEVEL; FGF23 GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; POPULATION GENETICS; POPULATION RESEARCH; SEX RATIO;

ADULT; AGED; CALCIUM; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; IRON; MALE; MIDDLE AGED; PHOSPHATES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84879417632     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0725-0     Document Type: Article

References (21)

1. Saito T, Fukumoto S. Fibroblast growth factor 23 (FGF23) and disorders of phosphate metabolism. Int J Pediatr Endocrinol. 2009;2009:496514.
2. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology. 2009;150:4835-45.
3. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195:125-31.
4. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol. 2007;194:1-10.
5. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277:494-8.
6. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-92.
7. Wolf M. Fibroblast growth factor 23 and the future of phosphorus management. Curr Opin Nephrol Hypertens. 2009;18:463-8.
8. Filler G, Liu D, Huang SH, Casier S, Chau LA, Madrenas J. Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease. Clin Biochem. 2011;44:435-7.
9. Isakova T, Wolf MS. FGF23 or PTH: which comes first in CKD ? Kidney Int. 2010;78:947-9.
10. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010;78:975-80.
11. Sato K, Nohtomi K, Demura H, Takeuchi A, Kobayashi T, Kazama J, Ozawa H. Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone. 1997;21:57-64.
12. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94:2332-7.
13. Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009;46:167-9.
14. Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45:814-6.
15. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879-85.
16. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600-8.
17. Okada M, Imamura K, Iida M, Fuchigami T, Omae T. Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenschr. 1983;61:99-102.
18. Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J. 1998;45:431-9.
19. Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H, Fujimori A, Nishioka M, Nishi S, Fukagawa M. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol. 2011;33:421-6.
20. Yamasaki K, Hagiwara H. Excess iron inhibits osteoblast metabolism. Toxicol Lett. 2009;191:211-5.
21. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009;114:S34-S42. Education Association